Source: Google NewsPublished on 2021-02-17
Related Articles:
- Ingrezza Eases Tardive Dyskinesia Linked to Levodopa Safely and Effectively Over Long-Term, Phase 3 Trial Shows August 21, 2018 Long-term daily use of Ingrezza (valbenazine) leads to a clinically meaningful easing of tardive dyskinesia (TD) — the repetitive and jerky movements caused by antipsychotics – and to high levels of patient satisfaction, data from a Phase 3 clinical trial of Neurocrine Biosciences’ treatment show. The results, “Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study,” were orally…
- FDA Approves Ongentys as Levodopa Add-on for ‘Off’ Periods April 27, 2020 The U.S. Food and Drug Administration (FDA) has approved Ongentys (opicapone) as an oral, add-on daily treatment for Parkinson’s disease patients experiencing off periods while on a levodopa/carbidopa regimen. The approval is for 25 mg and 50 mg capsules, either taken once a day. It comes after Ongentys significantly reduced off periods — when the effects of a medication wear off before…
- Neurocrine to Ask FDA to Begin Reviewing Parkinson’s Therapy Ongentys in 2019 February 21, 2018 Neurocrine Biosciences will ask the U.S. Food and Drug Administration in early 2019 to begin the regulatory review process that could lead to the approval of its Parkinson’s therapy Ongentys (opicapone). It confirmed the timetable after meeting with FDA officials on its plan to file a New Drug Application for Ongentys, which European regulators approved in 2016. The application is a formal request…
- Neurocrine, Voyager Team Up to Develop VY-AADC for Parkinson’s Disease February 4, 2019 Neurocrine Biosciences and Voyager Therapeutics have joined efforts in a new strategic collaboration to further develop and market Voyager’s gene therapies VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia. With this partnership, Neurocrine Biosciences will apply its expertise in neuroscience, drug development, and commercialization to help expedite the development of Voyager’s gene therapy programs. “We are excited to collaborate…
- Opicapone Superior to Comtan in Providing Motor Benefits to Parkinson’s Patients, Phase 3 Study Shows August 22, 2018 Once-daily treatment with opicapone provides continued reductions of off periods in Parkinson’s patients taking levodopa, Neurocrine Biosciences’ Phase 3 clinical study shows. The findings also reveal that opicapone’s effectiveness was superior to that of Comtan (entacapone, marketed by Novartis). The results were presented in three scientific posters at the 2018 World Congress on Parkinson’s Disease and Related Disorders (IAPRD), taking place in Lyon, France.…
- Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders® - Yahoo Finance September 17, 2019 Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders® Yahoo FinancePhase III Data Analyses Evaluate the Long-Term Benefit of INGREZZA® (valbenazine) 40 mg and Early Response to Treatment in Patients with Tardive ...
- FDA Accepts New Drug Application for Opicapone as Add-on Therapy July 15, 2019 The U.S. Food and Drug Administration has accepted Neurocrine Biosciences’ new drug application for opicapone as a potential add-on therapy to levodopa/carbidopa for Parkinson’s disease. The FDA has set a 12-month review process, with a decision expected by April 26, 2020. If approved, the FDA will start its Prescription Drug User Fee Act (PDUFA), which authorizes the agency to collect fees from…
- Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders - BioSpace June 11, 2019 Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders BioSpaceSAN DIEGO, June 11, 2019 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from two of its movement ...
- Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders - P&T Community June 11, 2019 Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders P&T CommunitySAN DIEGO, June 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from two of its movement ...
- Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders® - P&T Community September 17, 2019 Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders® P&T CommunitySAN DIEGO, Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement ...
- UK Experts Outline Practical Ways to Manage Wearing-off in Parkinson’s July 13, 2018 A panel of United Kingdom-based experts has defined a set of practical considerations to manage motor fluctuations and wearing-off in Parkinson’s disease patients. Based on practical clinical experience, the guidelines were outlined in “Noninvasive options for ‘wearing-off’ in Parkinson’s disease: a clinical consensus from a panel of UK Parkinson’s disease specialists,” published in the journal Neurodegenerative Disease Management. Currently, the…
- Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting - Yahoo Finance April 30, 2019 Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting Yahoo FinanceLong-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant ...
- Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting - Yahoo Finance April 30, 2019 Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting Yahoo FinanceLong-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant ...
- May 11, 2019 - Parkinson's Weekly Update May 11, 2019 Weekly Update - Highlights include: Mayo Clinic researchers explore the relationship between low levels of Vitamin B-12 and Parkinson’s; appendix removal might or might not affect Parkinson’s risk; monkey butt research finds PD related proteins linked to inflammation; impulse control disorders and PD; Pharmaceutical News from the Annual Meeting of the American Academy of Neurology; technology targets freezing of gait;…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Jazz scores FDA nod for sleepiness drug Sunosi, but a launch will have to wait - FiercePharma March 21, 2019 Jazz scores FDA nod for sleepiness drug Sunosi, but a launch will have to wait FiercePharmaJazz scored FDA approval for its next launch in Sunosi, a med to improve wakefulness in patients with narcolepsy or obstructive sleep apnea. (Olivier Le ...
- Boxing for Parkinson’s Disease November 10, 2020 Boxing and Parkinson’s Disease We know without a doubt that exercise is important for people with Parkinson’s disease (PD). Various types of exercise and movement can help people improve their balance, strength, mobility, flexibility, endurance and walking ability. Studies also reveal that exercise can help improve cognition, depression, fatigue, and sleep. We have discussed exercise in previous blogs and go into great…
- Boxing for Parkinson’s Disease November 10, 2020 Boxing and Parkinson’s Disease We know without a doubt that exercise is important for people with Parkinson’s disease (PD). Various types of exercise and movement can help people improve their balance, strength, mobility, flexibility, endurance and walking ability. Studies also reveal that exercise can help improve cognition, depression, fatigue, and sleep. We have discussed exercise in previous blogs and go into great…
- #AANAM – Opicapone Can Prolong ‘On-Time’ Levopoda Provides, Data from Phase 3 Trials Show May 6, 2019 Once-daily opicapone can prolong the time during which treatment with levopoda, a standard therapy, effectively prevents motor symptom fluctuations in people with Parkinson’s disease, results from two international Phase 3 studies show. The findings, “Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase 3 Studies,” were presented during the 2019 Annual Meeting of the American Academy of Neurology (AAN), now…
- Parkinson’s and the pandemic: your hopes and fears this World Parkinson’s Day April 9, 2020 To mark World Parkinson’s Day 2020, we asked our readers around the world to share a video highlighting how they’ve been impacted by the coronavirus pandemic and rally together to support each other at a very challenging time. The response was overwhelming – read on for some of the highlights April 11 is World Parkinson’s Day – an annual event…
- On the road: Acadia teams up with Michael J. Fox Foundation for local, patient-focused Parkinson's events - FiercePharma June 26, 2019 On the road: Acadia teams up with Michael J. Fox Foundation for local, patient-focused Parkinson's events FiercePharmaAcadia Pharmaceuticals is taking Parkinson's disease education on the road in a partnership with the Michael J. Fox Foundation. The “Parkinson's IQ + You” ...
- FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug - Yahoo Finance July 11, 2019 FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Yahoo FinanceNeurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease PRNewswireNeurocrine files for US approval for novel Parkinson's therapy The Pharma LetterView full coverage on Google News